BACKGROUND: The resistance against antimalarial drugs represents a global challenge in the fight and control of malaria. The Brazilian biodiversity can be an important tool for research and development of new medicinal products. In this context, toxinology is a multidisciplinary approach on the development of new drugs, including the isolation, purification, and evaluation of the pharmacological activities of natural toxins. The present study aimed to evaluate the cytotoxicity, as well as the antimalarial activity in silico and in vitro of four compounds isolated from Rhinella marina venom as potential oral drug prototypes. METHODS: Four compounds were challenged against 35 target proteins from P. falciparum and screened to evaluate their physicochemical properties using docking assay in Brazilian Malaria Molecular Targets (BraMMT) software and in silico assay in OCTOPUS® software. The in vitro antimalarial activity of the compounds against the 3D7 Plasmodium falciparum clones were assessed using the SYBR Green I based assay (IC50). For the cytotoxic tests, the LD50 was determined in human pulmonary fibroblast cell line using the [3(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide] (MTT) assay. RESULTS: All compounds presented a ligand-receptor interaction with ten Plasmodium falciparum-related protein targets, as well as antimalarial activity against chloroquine resistant strain (IC50 = 3.44 μM to 19.11 μM). Three of them (dehydrobufotenine, marinobufagin, and bufalin) showed adequate conditions for oral drug prototypes, with satisfactory prediction of absorption, permeability, and absence of toxicity. In the cell viability assay, only dehydrobufotenin was selective for the parasite. CONCLUSIONS: Dehydrobufotenin revealed to be a potential oral drug prototype presenting adequate antimalarial activity and absence of cytotoxicity, therefore should be subjected to further studies.
BACKGROUND: The resistance against antimalarial drugs represents a global challenge in the fight and control of malaria. The Brazilian biodiversity can be an important tool for research and development of new medicinal products. In this context, toxinology is a multidisciplinary approach on the development of new drugs, including the isolation, purification, and evaluation of the pharmacological activities of natural toxins. The present study aimed to evaluate the cytotoxicity, as well as the antimalarial activity in silico and in vitro of four compounds isolated from Rhinella marina venom as potential oral drug prototypes. METHODS: Four compounds were challenged against 35 target proteins from P. falciparum and screened to evaluate their physicochemical properties using docking assay in Brazilian Malaria Molecular Targets (BraMMT) software and in silico assay in OCTOPUS® software. The in vitro antimalarial activity of the compounds against the 3D7 Plasmodium falciparum clones were assessed using the SYBR Green I based assay (IC50). For the cytotoxic tests, the LD50 was determined in human pulmonary fibroblast cell line using the [3(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide] (MTT) assay. RESULTS: All compounds presented a ligand-receptor interaction with ten Plasmodium falciparum-related protein targets, as well as antimalarial activity against chloroquine resistant strain (IC50 = 3.44 μM to 19.11 μM). Three of them (dehydrobufotenine, marinobufagin, and bufalin) showed adequate conditions for oral drug prototypes, with satisfactory prediction of absorption, permeability, and absence of toxicity. In the cell viability assay, only dehydrobufotenin was selective for the parasite. CONCLUSIONS: Dehydrobufotenin revealed to be a potential oral drug prototype presenting adequate antimalarial activity and absence of cytotoxicity, therefore should be subjected to further studies.
Entities:
Keywords:
Antimalarial drug Docking; Bufadienolides; Natural compounds
Authors: Maria do Céu de Madureira; Ana Paula Martins; Milene Gomes; Jorge Paiva; António Proença da Cunha; Virgílio do Rosário Journal: J Ethnopharmacol Date: 2002-06 Impact factor: 4.360
Authors: Eduardo Habib Bechelane Maia; Vinícius Alves Campos; Bianca Dos Reis Santos; Marina Santos Costa; Iann Gabriel Lima; Sandro J Greco; Rosy I M A Ribeiro; Felipe M Munayer; Alisson Marques da Silva; Alex Gutterres Taranto Journal: J Mol Model Date: 2017-01-07 Impact factor: 1.810
Authors: Geraldino A Cunha-Filho; Inês S Resck; Bruno C Cavalcanti; Cláudia O Pessoa; Manoel O Moraes; José R O Ferreira; Felipe A R Rodrigues; Maria L Dos Santos Journal: Toxicon Date: 2010-04-08 Impact factor: 3.033
Authors: C A Bell; J E Hall; D E Kyle; M Grogl; K A Ohemeng; M A Allen; R R Tidwell Journal: Antimicrob Agents Chemother Date: 1990-07 Impact factor: 5.191
Authors: Israel José Pereira Garcia; Gisele Capanema de Oliveira; Jéssica Martins de Moura Valadares; Felipe Finger Banfi; Silmara Nunes Andrade; Túlio Resende Freitas; Evaldo Dos Santos Monção Filho; Hérica de Lima Santos; Gerardo Magela Vieira Júnior; Mariana Helena Chaves; Domingos de Jesus Rodrigues; Bruno Antonio Marinho Sanchez; Fernando P Varotti; Leandro Augusto Barbosa Journal: Steroids Date: 2019-09-06 Impact factor: 2.668